Glenn Goddard
Director of Finance/CFO chez INTELLIA THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Actuellement, Glenn Goddard occupe le poste de vice-président exécutif, directeur financier et comptable chez Intellia Therapeutics, Inc. Il a précédemment occupé le poste de Senior Vice President-Finance d'Agios Pharmaceuticals, Inc, de Chief Financial Officer de Generation Bio Co, de Controller d'ImmunoGen, Inc, de Vice President-Finance d'Archemix Corp, de Principal chez Ernst & Young LLP et de Principal chez Feeley & Driscoll PC. Glenn Goddard a obtenu un diplôme de premier cycle de l'université Bentley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 69 213 ( 0,07% ) | 2 M $ | 31/03/2024 |
Postes actifs de Glenn Goddard
| Sociétés | Poste | Début |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Director of Finance/CFO | 29/10/2018 |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Director/Board Member | - |
Anciens postes connus de Glenn Goddard
| Sociétés | Poste | Fin |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Director of Finance/CFO | 19/09/2016 |
| GENERATION BIO CO. | Director of Finance/CFO | - |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| IMMUNOGEN, INC. | Comptroller/Controller/Auditor | - |
Formation de Glenn Goddard
| Bentley University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Commercial Services |
| Generation Bio Co. | |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Health Technology |
